Call for Abstract

2nd International Conference and Exhibition on Biowaivers and Biosimilars, will be organized around the theme “Addressing Novel Strategic Considerations for Biosimilar Market”

Biosimilars-2013 is comprised of 9 tracks and 62 sessions designed to offer comprehensive sessions that address current issues in Biosimilars-2013.

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 1-1Licensing of biosimilars
  • Track 1-2Biosimilars regulation
  • Track 1-3Patent issues
  • Track 1-4FDA's view on biosimilars
  • Track 1-5BLA filing for biosimilars
  • Track 1-6Regulatory prospects of BRIC countries
  • Track 1-7A paradigm of traditional generics to biosimilars
  • Track 1-8Biowaiver approval for Biosimilars
  • Track 2-1Recombinant blood products
  • Track 2-2Recombinant vaccines
  • Track 2-3Growth hormones
  • Track 2-4Biosimilar insulin
  • Track 2-5Biosimilar peptides
  • Track 2-6Recombinant therapeutic proteins
  • Track 2-7Biosimilars in cancer treatment
  • Track 2-8Biosimilar monoclonal antibodies
  • Track 2-9Biosimilars interferon
  • Track 2-10Biosimilars in rheumatic diseases
  • Track 3-1Clinical trials
  • Track 3-2Risk management, and quality affairs
  • Track 3-3Case studies, and clinical models
  • Track 3-4Transgenic animals
  • Track 3-5 Targeted cell line development
  • Track 3-6Clinical PK/PD studies
  • Track 3-7Toxicological studies
  • Track 3-8Aspects of genotoxicity tests
  • Track 4-1Global impact of biosimilars over generics
  • Track 4-2Economic aspect towards biosimilars
  • Track 4-3Biosimilars in global market
  • Track 4-4Investment and returns on biosimilars
  • Track 4-5Cost and risk management
  • Track 4-6Adopting innovative mechanisms such as risk-sharing arrangement
  • Track 4-7European market for biosimilars
  • Track 4-8Global P&R models for the biosimilars and generics market
  • Track 5-1Biotechnology medicinal products for different drugs
  • Track 5-2Challenges faced in developing biosimilars
  • Track 5-3Future of next generation biosimilars
  • Track 5-4Biopharmaceuticals development
  • Track 6-1Bioanalytical methods
  • Track 6-2Formulation
  • Track 6-3Bioassay for comparability and potency testing
  • Track 6-4GMP protein analysis
  • Track 6-5LC/MS analysis for discovery, preclinical, and clinical programs
  • Track 6-6Electrophoresis
  • Track 6-7Multimodal techniques
  • Track 7-1Strategies for the bioequivalence assessment of topical dosage forms
  • Track 7-2Bioequivalence assessment of respiratory dosage forms
  • Track 7-3Bioequivalence approaches for transdermal dosage forms
  • Track 7-4Evaluation of highly variable drugs and drug products
  • Track 8-1IVIVC based biowaivers
  • Track 8-2BCS biowaivers
  • Track 8-3Preclinical and clinical testing for oral drug delivery
  • Track 8-4Waiver for In vivo bioavailability or bioequivalence
  • Track 8-5Consideration of biowaiver extensions for BCS class III drugs
  • Track 8-6In vitro diffusion cells for dissolution testing in formulation development
  • Track 8-7Dissolution testing in drug formulation
  • Track 8-8In vitro preclinical ADME/BCS testing
  • Track 8-9In vitro drug product research
  • Track 9-1Transgenic plants
  • Track 9-2Post translational genetics
  • Track 9-3Fermentation culture
  • Track 9-4Molecular farming